Olive oil consumption is associated with a lower risk of cardiovascular disease and stroke.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
01 2022
Historique:
received: 09 06 2021
revised: 13 09 2021
accepted: 03 11 2021
pubmed: 7 12 2021
medline: 26 2 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

The specific association of olive oil consumption with coronary heart disease (CHD) or stroke has not been totally established. to examine whether olive oil consumption is associated with subclinical atherosclerosis, the risk of total cardiovascular disease (CVD), CHD, and stroke. Three cohorts were included: AWHS (2318 men), SUN Project (18,266 men and women), and EPIC-Spain (39,393 men and women). Olive oil consumption was measured at baseline using validated questionnaires. In the AWHS, 747 participants had a positive coronary artery calcium score (CACS>0), and the OR (95% CI) was 0.89 (0.72, 1.10) in those with virgin olive oil consumption ≥30 g/day (v. <10 g/day). In the SUN Project (follow-up 10.8 years) 261 total CVD cases occurred, and the HR was 0.57 (0.34, 0.96) for consumptions ≥30 g/day (v. <10 g/day). In the EPIC-Spain (follow-up 22.8 years) 1300 CHD cases and 938 stroke cases occurred; the HRs for stroke according, 0 to <10 (ref), 10 to <20, 20 to <30, and ≥30 g/day of olive oil consumption, were 0.84 (0.70, 1.02), 0.80 (0.66, 0.96), 0.89 (0.74, 1.07). A weaker association was observed for CHD. The association was stronger among those consuming virgin olive oil, instead of common (refined). Olive oil is associated with lower risk of CVD and stroke. The maximum benefit could be obtained with a consumption between 20 and 30 g/day. The association could be stronger for virgin olive oil and might operate from the early stages of the disease.

Sections du résumé

BACKGROUND & AIMS
The specific association of olive oil consumption with coronary heart disease (CHD) or stroke has not been totally established.
OBJECTIVE
to examine whether olive oil consumption is associated with subclinical atherosclerosis, the risk of total cardiovascular disease (CVD), CHD, and stroke.
METHODS
Three cohorts were included: AWHS (2318 men), SUN Project (18,266 men and women), and EPIC-Spain (39,393 men and women). Olive oil consumption was measured at baseline using validated questionnaires.
RESULTS
In the AWHS, 747 participants had a positive coronary artery calcium score (CACS>0), and the OR (95% CI) was 0.89 (0.72, 1.10) in those with virgin olive oil consumption ≥30 g/day (v. <10 g/day). In the SUN Project (follow-up 10.8 years) 261 total CVD cases occurred, and the HR was 0.57 (0.34, 0.96) for consumptions ≥30 g/day (v. <10 g/day). In the EPIC-Spain (follow-up 22.8 years) 1300 CHD cases and 938 stroke cases occurred; the HRs for stroke according, 0 to <10 (ref), 10 to <20, 20 to <30, and ≥30 g/day of olive oil consumption, were 0.84 (0.70, 1.02), 0.80 (0.66, 0.96), 0.89 (0.74, 1.07). A weaker association was observed for CHD. The association was stronger among those consuming virgin olive oil, instead of common (refined).
CONCLUSIONS
Olive oil is associated with lower risk of CVD and stroke. The maximum benefit could be obtained with a consumption between 20 and 30 g/day. The association could be stronger for virgin olive oil and might operate from the early stages of the disease.

Identifiants

pubmed: 34872046
pii: S0261-5614(21)00503-3
doi: 10.1016/j.clnu.2021.11.002
pii:
doi:

Substances chimiques

Olive Oil 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

122-130

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest All authors have completed the Unified Competing Interest form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Carolina Donat-Vargas (C)

IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain; Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid-IdiPaz, Madrid, Spain; CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain; Unit of Nutritional and Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: carolina.donat.vargas@ki.se.

Helena Sandoval-Insausti (H)

Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid-IdiPaz, Madrid, Spain; CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: helenagabar@gmail.com.

José L Peñalvo (JL)

Unit of Non-Communicable Diseases, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. Electronic address: jpenalvo@itg.be.

Maria Concepción Moreno Iribas (MC)

Research Network on Health Services in Chronic Diseases (REDISSEC), Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: mmorenoi@navarra.es.

Pilar Amiano (P)

CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain; Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain; Biodonostia Health Research Institute, Epidemiology and Public Health Area, San Sebastián, Spain. Electronic address: epicss-san@euskadi.eus.

Maira Bes-Rastrollo (M)

University of Navarra, Department of Preventive Medicine and Public Health, School of Medicine, Pamplona, Spain; CIBEROBN (CIBER of Obesity and Nutrition), Madrid, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: mbes@unav.es.

Esther Molina-Montes (E)

CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain; Department of Nutrition and Food Science, University of Granada, Granada, Spain; Biomedical Research Center, Institute of Nutrition and Food Technology (INYTA) "José Mataix", University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. Electronic address: memolina@ugr.es.

Belén Moreno-Franco (B)

University of Zaragoza, Zaragoza, Spain; CIBERCV and Instituto de Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain. Electronic address: mbmoreno@unizar.es.

Antonio Agudo (A)

Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO), And Nutrition and Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain. Electronic address: a.agudo@iconcologia.net.

Cristina Lasheras Mayo (CL)

Department of Functional Biology, Faculty of Medicine, University of Oviedo, Spain. Electronic address: lasheras@uniovi.es.

Martín Laclaustra (M)

University of Zaragoza, Zaragoza, Spain; CIBERCV and Instituto de Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain. Electronic address: martin.laclaustra@unizar.es.

Carmen De La Fuente Arrillaga (C)

University of Navarra, Department of Preventive Medicine and Public Health, School of Medicine, Pamplona, Spain; CIBEROBN (CIBER of Obesity and Nutrition), Madrid, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: cfuente@unav.es.

Maria Dolores Chirlaque Lopez (MD)

CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain; Murcia Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain. Electronic address: mdolores.chirlaque@carm.es.

Maria-José Sánchez (MJ)

CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Andalusian School of Public Health (EASP), Granada, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. Electronic address: mariajose.sanchez.easp@juntadeandalucia.es.

Miguel Angel Martínez-Gonzalez (MA)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; University of Navarra, Department of Preventive Medicine and Public Health, School of Medicine, Pamplona, Spain; CIBEROBN (CIBER of Obesity and Nutrition), Madrid, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: mamartinez@unav.es.

Guallar-Castillón Pilar (GC)

IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain; Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid-IdiPaz, Madrid, Spain; CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain. Electronic address: mpilar.guallar@uam.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH